# Are COVID-19 Polymorphisms in ACE and ACE2 Prognosis Predictors?

**Authors:** Fabiana Amaral Guarienti, Fernando Antônio Costa Xavier, Mateus Duarte Ferraz, Fernanda Wagner, Daniel Rodrigo Marinowic, Jaderson Costa da Costa, Denise Cantarelli Machado

PMC · DOI: 10.3390/cimb46080480 · Current Issues in Molecular Biology · 2024-07-28

## TL;DR

This study explores whether genetic variations in ACE and ACE2 genes are linked to the severity and outcome of COVID-19.

## Contribution

The study identifies a potential link between ACE and ACE2 intronic deletions and mortality in COVID-19 patients.

## Key findings

- ACE and ACE2 intronic deletions were found in all deceased patients.
- Genetic polymorphisms in ACE and ACE2 correlate with differences in COVID-19 outcomes.
- The study suggests genetic factors may influence the clinical course of COVID-19.

## Abstract

Regardless of the containment of the SARS-CoV-2 pandemic, it remains paramount to comprehensively understand its underlying mechanisms to mitigate potential future health and economic impacts, comparable to those experienced throughout the course of the pandemic. The angiotensin-converting enzyme 2 (ACE2) provides anchorage for SARS-CoV-2 binding, thus implicating that ACE and ACE2 might contribute to the variability in infection severity. This study aimed to elucidate predisposing factors influencing the disease course among people infected by SARS-CoV-2, focusing on angiotensin-converting enzyme (ACE) and ACE2 polymorphisms. Notably, despite similar demographics and comorbidities, COVID-19 patients exhibit substantial differences in prognosis. Genetic polymorphisms in ACE and ACE2 have been implicated in disease progression, prompting our investigation into their role in COVID-19 evolution. Using next-generation sequencing (NGS), we analyzed ACE and ACE2 genes in a sample group comprising six subjects infected by SARS-CoV-2. Our findings revealed a correlation between specific polymorphisms and COVID-19 outcomes. Specifically, ACE and ACE2 intronic deletions were observed in all deceased patients, suggesting a potential association with mortality. These results highlight the significance of genetic factors in shaping the clinical course of COVID-19, emphasizing the importance of further research into the impact of genetic variations on COVID-19 severity.

## Linked entities

- **Genes:** ACE (angiotensin I converting enzyme) [NCBI Gene 1636], ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272]
- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Genes:** ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272] {aka ACEH}, ACE (angiotensin I converting enzyme) [NCBI Gene 1636] {aka ACE1, CD143, DCP, DCP1}
- **Diseases:** infected (MESH:D007239), COVID-19 (MESH:D000086382)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11352864/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC11352864/full.md

---
Source: https://tomesphere.com/paper/PMC11352864